Home > Groups > Publications (Vascular medicine and epigenetics)

Groups

Vascular medicine and epigenetics group
(Division of Vascular Medicine and Epigenetics)

Publications

Original Articles (since 2003)

  1. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008 (in press)
  2. Takami, Y., Nakagami, H., Morishita, R., Katsuya, T., Hayashi, H., Mori, M., Koriyama, H., Baba, Y., Yasuda, O., Rakugi, H., Ogihara, T., and Kaneda, Y.: Potential role of CYLD (cylindromatosis) as a deubiquitinating enzyme in vascular cells. Am J Pathol 2008;172:818-29.
  3. Saito Y, Nakagami H, Kurooka M, Takami Y, Kukuchi Y, Hayashi H, Nishikawa T, Tamai K, Morishita R, Azuma N, Sasajima T, Kaneda Y. Cold shock domain A represses angiogenesis and lymphangiogenesis via inhibition of serum response element. Oncogene 2008;27:1821-33.
  4. Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. NF-{kappa}B Is a Key Mediator of Cerebral Aneurysm Formation. Circulation. 2007; 116(24):2830-40.
  5. Nakagami H, Kikuchi Y, Katsuya T, Morishita R, Akasaka H, Saito S, Rakugi H,Kaneda Y, Shimamoto K, Ogihara T. Gene polymorphism of myospryn (cardiomyopathy associated 5) is associated with left ventricular wall thickness in hypertensive patients. Hypertens Res 2007; 30(12): 1239-46.
  6. Hayashi H, Nakagami H, Takami Y, Sato N, Saito Y, Nishikawa T, Mori M, Koriyama H, Tamai K, Morishita R, Kaneda Y. Involvement of gamma-secretase in postnatal angiogenesis. Biochem Biophys Res Commun. 2007 ;363(3):584-90.
  7. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T, Saito Y, Hayashi H, Kikkuchi Y, Nishikawa T, Baba Y, Yasuda O, Rakugi H, Ogihara T, Kaneda Y. Ubiquitin carboxyl-terminal hydrolae L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kB activation. Arterioscler Thromb Vasc Biol. 2007;27(10):2184-90
  8. Osaka KM, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, Yuyama K, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Increase in Nuclease Resistance and Incorporation of NF-kappaB Decoy Oligodeoxynucleotides by Modification of 3'-Terminus. J Gene Med 2007;9(9):812-9.
  9. Nakagami H, Osako KM, Shimizu H, Hanayama R, Morishita R. Potential contribution of action of renin angiotensin system to bone metabolism. Current Hypertension Reviews 2007 (in press)
  10. Takeda S, Terazono B, Mishima F, Nakagami H, Nishijima S, Kaneda Y. Novel drug delivery system by surface modified magnetic nanoparticles. J Nanosci Nanotechnol. 2006; 6(9-10):3269-76.
  11. Saito Y, Nakagami H, Morishita R, Takami Y, Kikuchi Y, Hayashi H, Nishikawa T, Tamai K, Azuma N, Sasajima T, Kaneda Y. Hepatocyte growth factor ameliorates secondary lymphedema via promotion of lympangiogenesis. Circulation 2006; 114:1177-84.
  12. Nakagami H, Nakagawa N, Takeya Y, Kashiwagi K, Ishida C, Hayashi SI, Aoki M, Matsumoto K, Nakamura T, Ogihara T, Morishita R. A model of vasculogenesis from ES cells for vascular research and regenerative medicine. Hypertension 2006; 48:112-9.
  13. Xiang F, Sakata Y, Cui L, Youngblood M, Nakagami H, Liao JK, Chin MT. Transcription factor CHF1/Hey2 suppress cardiac hypertrophy through an inhibitory interaction in GATA4. Am J Physiol Heart Circ Physiol. 2006; 290:H1997-H2006.
  14. Nakagami H, Morishita R, Maeda K, Kikuchi Y, Ogihara T, Kaneda Y. Adipose tissue derived stromal cells as a novel option for regenerative medicine. J Atheroscler Thromb. 2006; 13:77-81.
  15. Nakagami H, Tomita N, Kaneda Y, Ogihara T, Morishita R. Anti-oxidant gene therapy by NFkB decoy oligodeoxynucleotide. Curr Pharm Biotechnol. 2006;7:95-100.
  16. Nishikawa T, Nakagami H, Matsuki A, Maeda A, Yo CY, Harada T, Morishita R, Tamai K, Kaneda Y. Development of high throughput functional screening of therapeutic genes using HVJ-E vector. Hum Gene Ther 2006;17:470-475.
  17. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Favorable effect of statins beyond lipid lowering. Future Lipidology 2006; 1:75-80.
  18. Shimizu H, Nakagami H, Tsukamoto I, Morita S, Kunugiza Y, Tomita T, Yoshikawa H, Kaneda Y, Ogihara T, Morishita R. NFkB Decoy Oligodeoxynucleotides Ameliorates Osteoporosis Through Inhibition of Activation and Differentiation of Osteoclasts. Gene Ther. 2006; 13:933-41.
  19. Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, Kikuchi Y, Saito Y, Tamai K, Ogihara T, Kaneda Y. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol. 2005;25:2542-2547.
  20. Morishita N, Nakagami H, Morishita R, Takeda S, Mishima F, Terazono B, Nishijima S, Kaneda Y, Tanaka N. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem Biophys Res Commun. 2005; 9:1121-1126.
  21. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Hepatocyte growth factor as potential cardiovascular therapy. Expert Rev Cardiovasc Ther. 2005;3:513-519.
  22. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Endothelial Dysfunction in Hyperglycemia as a Trigger of Atherosclerosis. Current Diabetes Reviews, 2005;1:59-63.
  23. Yamamoto K, Tomita N, Yoshimura S, Nakagami H, Taniyama Y, Yamasaki K, Ogihara T, Morishita R. Hypoxia-induced renal epithelial cell death through caspase-dependent pathway: role of Bcl-2, Bcl-xL and Bax in tubular injury. Int J Mol Med. 2004;14:633-640.
  24. Nakagami H, Liao JK. Statins and myocardial hypertrophy. Coron Artery Dis. 2004;15:247-250.
  25. Nakagami H, Morishita R, Nishikawa T, Shimizu H, Iguchi S, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Lack of association between the hepatocyte growth factor receptor, c-met, and the anti-apoptotic action of bag-1 in endothelial cells. Hypertens Res. 2004;27:359-365.
  26. Matsuki A, Yamamoto S, Nakagami H, Aoki M, Tamai K, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun. 2004;315:59-65.
  27. Nakagami H, Takemoto M, Liao JK. NADPH Oxidase-derived Superoxide Anion Mediates Angiotensin II-induced Cardiac Hypertrophy. J Mol Cell Cardiology, 2003;35:851-859.
  28. Nakagami H, Jensen KS, Liao JK. A Novel Pleiotropic Effect of Statins: Prevention of Cardiac Hypertrophy by Cholesterol-independent Mechanisms. Ann Medicine, 2003;35:398-403.
  29. Nakabayashi M, Morishita R, Nakagami H, Kuba K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia. 2003;46:115-123.
  30. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003;107:106-112.
[Vascular medicine and epigenetics group]
Page Top